

Date: 14-11-2025

To,  
The Deputy Manager  
Department of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001

Subject: Outcome of Board Meeting held on Friday, 14<sup>th</sup> November, 2025.

Ref.: Scrip Code: 512600

Security Id: ASTALLTD

Respected Sir/Madam,

This is to inform that Board of Directors of the Company in its meeting held on 14<sup>th</sup> November, 2025 at the corporate office of the company i.e., House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032, which commenced at 5:00 P.M. has considered and approved the Unaudited Financial Results of the company for the quarter and half year ended 30<sup>th</sup> September, 2025 along with the Limited Review Report of the auditors thereon.

The Meeting was concluded at 05:30 P.M. with the vote of thanks.

We request you to take the aforesaid information on record for dissemination through your website.

Thanking you

Yours sincerely,

For Astal Laboratories Limited



Mahendra Kumar  
(Company Secretary & Compliance Officer)  
Membership No.: A71224



**Limited Review Report on Standalone Unaudited Quarterly Financial Results of Astal Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,  
Board of Directors  
**Astal Laboratories Limited**

We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **Astal Laboratories Limited** for the quarter ended on 30<sup>th</sup> September, 2025, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").


This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.


We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Sathuluri & Co**  
Chartered Accountants  
Firm Reg No.006383S

  
**S.S.Prakash**  
Partner  
M.No.202710



**UDIN : 25202710BMKXBM1646**

Place: Hyderabad  
Date: 14-11-2025



**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER 2025**

Sr. No	Particulars	Rs. (In Lakhs except EPS)					
		Quarter Ended			Half Year Ended		Year ended
		30/09/2025	30/06/2025	30/09/2024	30/09/2025	30/09/2024	31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Revenue</b>						
	a) From operations	3,751.64	2,532.66	1,315.98	6,284.30	2,630.55	6,423.10
	b) Other Income (Refer to Note No.3)	3.27	5.61	0.00	8.88	3.42	12.51
	<b>Total Revenue</b>	<b>3,754.91</b>	<b>2,538.27</b>	<b>1,315.98</b>	<b>6,293.18</b>	<b>2,633.97</b>	<b>6,435.61</b>
2	<b>Expenses</b>						
	(a) Cost of Material Consumed	3,908.02	2,308.22	1,310.14	6,216.23	2,469.26	6,181.42
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(626.03)	(161.63)	(360.40)	(787.66)	(526.60)	(1,370.22)
	(d) Employees Benefits expenses	41.83	44.72	43.34	86.55	84.10	133.85
	(e) Finance Cost	30.91	30.08	9.13	60.99	15.42	70.07
	(f) Depreciation amortization expenses	12.24	12.01	2.50	24.25	3.78	22.31
	(g) Other Expenses	40.94	25.59	34.00	66.53	76.90	200.42
	<b>Total Expenses</b>	<b>3,407.92</b>	<b>2,258.98</b>	<b>1,038.71</b>	<b>5,666.90</b>	<b>2,122.86</b>	<b>5,237.86</b>
3	<b>Profit from ordinary activities before exceptional Items ( 1 - 2 )</b>	346.99	279.29	277.28	626.28	511.11	1,197.75
4	<b>Exceptional Items - Income/ (Expenses)</b>	-	-	-	-	-	-
5	<b>Profit from ordinary activities before tax ( 3 - 4 )</b>	346.99	279.29	277.28	626.28	511.11	1,197.75
6	<b>Tax Expenses</b>						
	(a) Current Tax	90.41	45.61	77.10	136.02	139.39	294.08
	(b) Deferred Tax	(1.68)	24.71	(0.12)	23.03	2.53	11.14
7	<b>Profit/(Loss) for the period ( 5 -6 )</b>	258.26	208.96	200.29	467.22	369.20	892.53
8	A (i) Items that will not be reclassified	-	-	-	-	-	-

	to profit or loss (net of tax)						
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will not be reclassified to profit or loss (net of tax)						
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
9	<b>Total Comprehensive Income, net of tax (7 + 8)</b>	258.26	208.96	200.29	467.22	369.20	892.53
10	<b>Paid up equity share capital</b>	1,078.55	984.56	984.56	984.56	984.56	984.56
	(Face Value of Rs.10/- each)						
11	<b>Earning per share</b>						
	(of Rs.10/-each) not annualised						
	(a) Basic	2.395	2.126	2.040	4.338	3.756	9.080
	(b) Diluted	1.972	1.737	2.040	3.568	3.756	8.043

**NOTES:**

1	The above Unaudited Financial Results of the company for the quarter ended September 30th 2025 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on 14th November, 2025.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical

	Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website <a href="https://astallabs.com">https://astallabs.com</a>

By the order of the Board  
For Astal Laboratories Limited



SUDHEER KARNA KANKANALA

Whole Time Director

DIN: 07591466

Date: 14/11/2025

Place: Hyderabad





**STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2025**

		(Rs. In lakhs.)	
PARTICULARS		As at 30th September 2025	As at 31-March 2025
		(Unaudited)	(Audited)
	<b>ASSETS</b>		
<b>1</b>	<b>Non - current assets</b>		
(a)	Property, plant and equipment	1126.98	1144.43
(b)	Capital work in progress		
(c)	Investment property		
(d)	Intangible assets		
(e)	Financial assets		
	(i) Investments		
	(ii) Loans	409.26	409.25
	(iii) Other financial assets		
(f)	Deferred tax Assets(Net)		
(g)	Other Non-current assets		0.00
	<b>Total non-current assets</b>	<b>1536.24</b>	<b>1553.69</b>
<b>2</b>	<b>Current assets</b>		
(a)	Inventories	2263.64	1475.98
(b)	<b>Financial assets</b>		
	(i) Investments		
	(ii) Trade receivables	5580.95	2766.41
	(iii) Cash and cash equivalents	498.87	379.46
	(iv) Other balances with banks		
	(v) Loans		
	(vi) Other financial assets	10.53	10.00
(c)	Other Current assets	180.23	148.53
	<b>Total current assets</b>	<b>8534.21</b>	<b>4780.38</b>
	<b>TOTAL ASSETS</b>	<b>10070.45</b>	<b>6334.06</b>
	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
(a)	Share capital	1078.55	984.56
(b)	Other equity	3286.62	2614.91
	<b>Total Equity</b>	<b>4365.17</b>	<b>3599.47</b>
<b>2</b>	<b>Non-current liabilities</b>		
(a)	Financial liabilities		
	(i) Long-term borrowings	41.15	45.61
	(ii) Deferred tax liabilities (net)	34.89	11.86
	(iii) Other financial liabilities		



*[Handwritten signature]*

(b)	Provisions		
(c)	Other Non Current liabilities		
	<b>Total non-current liabilities</b>	<b>76.04</b>	<b>57.47</b>
<b>3</b>	<b>Current liabilities</b>		
(a)	Financial liabilities		
	(i) Borrowings	1232.67	1281.21
	(ii) Trade payables	3970.23	1077.49
	(iii) Other financial liabilities		0.00
(b)	Provisions		
(c)	Other current Liabilities	426.34	318.42
	<b>Total current liabilities</b>	<b>5629.24</b>	<b>2677.12</b>
	<b>Total Liabilities</b>	<b>5705.28</b>	<b>2734.59</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>10070.45</b>	<b>6334.06</b>

By the order of the Board  
For Astal Laboratories Limited




**SUDHEER KARNA KANKANALA**

**Whole Time Director**

**DIN: 07591466**

**Date: 14/11/2025**

**Place: Hyderabad**





**Astal Laboratories Limited**

# ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com; Mob. No: 6302730973, Website: https://astallabs.com/

## CASH FLOW STATEMENT AS AT SEPTEMBER 30,2025

Rs. (In Lakhs)

PARTICULARS	30 <sup>th</sup> September, 2025	31 <sup>st</sup> March, 2025
	(Unaudited)	(Audited)
<b>A. CASH FLOW FROM OPERATING ACTIVITIES: -</b>		
Net Profit/(Loss) before tax as per statement of Profit & Loss	626.28	1,197.75
Adjustment for :		
Depreciation	24.25	22.31
Finance Cost	60.99	70.07
Interest Income	(8.88)	(12.51)
Operating Profit before working capital changes.	702.65	1,277.63
Adjustment for :-		
Changes in Trade Receivables	(2,814.55)	(1,184.90)
Changes in Trade Payables	2,892.74	(74.03)
Changes in Inventory	(787.66)	(1,370.22)
Changes in Other assets	(31.70)	229.38
Changes in Other Non Current assets	12.47	(10.00)
Changes in Other Current liabilities	(107.92)	(89.46)
Cash generated form operations	(133.97)	(1,221.60)
Taxes paid ( Net )	(30.13)	(30.13)
<b>Net cash generated from / (used in) Operating Activities</b>	<b>(164.10)</b>	<b>(1,251.73)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES: -</b>		
Interest Income	8.88	12.51
Purchase of Fixed Assets	(6.80)	(577.50)
(Issue) / Recovery of Loans and advances	(0.00)	(10.00)
Fixed Deposit with Banks	(38.23)	(206.46)
Advance paid for capital assets	-	-
<b>Net cash from Investing Activities</b>	<b>(36.16)</b>	<b>(781.44)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES: -</b>		
Interest Expense	(60.99)	(70.07)
Long Term Borrowings Taken		31.67
Long Term Borrowings Repaid	(1.50)	(5.47)
Issue of Shares	93.99	-
Share Warrets Amount received	298.48	372.99
<b>Net cash from (used in) Financing Activities</b>	<b>329.98</b>	<b>329.12</b>
<b>Net (Decrease)/Increase in Cash &amp; Cash Equivalent (A+B+C)</b>	<b>129.72</b>	<b>(1,704.05)</b>

*Indhira*





**Astal Laboratories Limited**

## **ASTAL LABORATORIES LIMITED**

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com; Mob. No: 6302730973, Website: <https://astallabs.com/>

<b>Opening Balance of Cash &amp; Cash Equivalents</b>	<b>173.00</b>	<b>607.65</b>
Cash on hand	0.02	0.03
Balance With Banks	172.99	607.61
Bank overdrafts and cash credit facility (secured)*	-	-
<b>Closing Balance of Cash &amp; Cash Equivalents</b>	<b>302.72</b>	<b>(1,096.40)</b>
Cash on hand	0.02	0.02
Balance With Banks	254.16	172.99
Bank overdrafts and cash credit facility (secured)*	48.54	(1,269.40)

Note: Bank overdrafts and cash credit facility are part of cash management system of the Company. Hence, considered as part of cash and cash equivalents.

By the order of the Board  
For Astal Laboratories Limited

**SUDHEER KARNA KANKANALA**

Whole Time Director

DIN: 07591466

Date: 14/11/2025

Place: Hyderabad

